SELECT PUBLICATIONS
Lilenbaum R et al. Randomized phase II trial of single agent erlotinib vs standard chemotherapy
in patients with advanced non-small cell lung cancer (NSCLC) and performance
status (PS) of 2. Presentation. Proc ASCO 2006;Abstract 7022.
Tsao M et al. An analysis of the prognostic and predictive importance of K-ras mutation
status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study
of erlotinib versus placebo in the treatment of non-small cell lung cancer. Proc ASCO
2006;Abstract 7005.
